Alamar Biosciences
Alamar Biosciences is a precision proteomics company whose NULISA platform and ARGO HT instrument enable attomolar-sensitivity multiplexed protein biomarker analysis for pharmaceutical, biotech, and academic research customers across 25 countries.
- Company typePublic
- Founded2018
- HeadquartersFremont, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alamar Biosciences does
Alamar Biosciences is a commercial-stage precision proteomics company that develops and sells the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) platform, an immunoassay technology that achieves attomolar sensitivity — roughly 10,000x more sensitive than traditional ELISA/PLA — by combining a sequential immunocomplex capture-and-release mechanism with NGS or qPCR readout. Its flagship instrument, the ARGO HT System, is a fully automated, high-throughput proteomics analyzer that processes up to 288 samples per run with under 30 minutes of hands-on time and integrates cloud-connected data analysis software.
The company monetizes through a razor-and-blade model: it sells ARGO HT instruments to pharmaceutical and biotech companies, academic medical centers, and research institutions, and generates recurring revenue from NULISAseq multiplex panels (Neuro 220, CNS Disease 120, Inflammation 250/250+, Mouse 120), NULISAqpcr single-plex and multiplex assays (BD-pTau217, NfL, AD 5-plex, IL-1B, IL-4), Dried Blood Spot extraction kits, and a Technology Access Program (TAP) for fee-for-service proof-of-concept work. Distribution is hybrid: direct enterprise sales in North America and major European markets, supplemented by exclusive regional distributors across APAC, EMEA, and LATAM, and a Certified Service Provider network of 11 partners including IQVIA Laboratories, Biognosys, and Frontage Labs.
Founded in 2018 in Fremont, California by the inventors of RNAscope technology, Alamar has scaled to over 300 customers across 25 countries with 100+ installed ARGO HT instruments, achieved ISO 13485 and SOC 2 compliance, and grew revenue from $25.1 million in 2024 to $74.2 million in 2025 (196% YoY). Following a $128 million Series C in 2024 and a $50+ million convertible note round in January 2026, the company completed its NASDAQ IPO (ticker ALMR) on April 17, 2026 at a $1.5 billion valuation, raising approximately $191.3 million in gross proceeds.
Alamar Biosciences firmographics
Firmographics- Name
- Alamar Biosciences
- Legal name
- Alamar Biosciences, Inc.
- Website
- https://alamarbio.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Ipo
- Headcount range
- 101–250 employees
- Short description
- Alamar Biosciences is a precision proteomics company whose NULISA platform and ARGO HT instrument enable attomolar-sensitivity multiplexed protein biomarker analysis for pharmaceutical, biotech, and academic research customers across 25 countries.
- Ownership category
- akta.pro rank
Alamar Biosciences industry classification
Industry- Product category
- Precision Proteomics Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industries
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where Alamar Biosciences is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alamar Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- ARGO HT Instrument Sales: Sale of the ARGO HT automated proteomics instrument - a fully integrated qPCR system enabling sample-to-data workflows. Each instrument generates over $400,000 in average annual consumables pull-through, representing a land-and-expand model with high LTV.
- NULISAseq Panel Consumables: Recurring revenue from multiplexed assay panels including Neuro 220, CNS Disease Panel 120, Inflammation Panel 250, and Inflammation Panel AQ. Consumables revenue grew 178% year-over-year in Q1 2026, indicating strong recurring demand.
- NULISAqpcr Assay Consumables: Single-plex and 5-plex qPCR-based assays including BD-pTau217, NfL, AD 5-plex, and custom assays. Consumables revenue grew 178% YoY in Q1 2026.
- Technology Access Program (TAP): Fee-for-service model providing proof-of-concept data using NULISA assays before customers purchase the ARGO HT system. Includes Pro Services (full service analysis) and Custom Assay Development services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | ARGO HT System instrument |
| Subscription | Annual | NULISAseq Panels (Neuro 220, CNS 120, Inflammation 250/250+, Mouse 120) |
| Subscription | Annual | NULISAqpcr Assays (BD-pTau217, NfL, IL-4, IL-1B, AD 5-plex) |
| Other | Pay-as-you-go | Technology Access Program (TAP) Services |
Go-to-market motion1 record
Distribution channels6 records
Marketing channels7 records
Alamar Biosciences product offering
Product offeringCore offering
Alamar Biosciences develops and commercializes the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) proteomics platform alongside the ARGO HT automated instrument system. The company sells multiplexed assay panels (NULISAseq) and single-plex qPCR assays (NULISAqpcr) for ultra-high sensitivity detection of protein biomarkers in research applications targeting neurology, immunology, and oncology. Products are sold to pharmaceutical companies, biotech firms, academic medical centers, and contract research organizations across more than 25 countries.
Product overview
Alamar Biosciences offers a platform-based portfolio centered on the NULISA technology and ARGO HT System. The NULISA Platform provides ultra-high sensitivity proteomics with attomolar detection and high multiplexing through proprietary sequential immunocomplex capture combined with NGS/qPCR readout. The ARGO HT System serves as the core automated instrument enabling sample-to-data workflows. The product portfolio includes NULISAseq multiplex panels (Neuro 220, CNS Disease Panel 120, Inflammation Panel 250, Inflammation Panel AQ, Mouse Panel 120) for multi-biomarker profiling, NULISAqpcr single-plex and 5-plex assays (AD 5-plex, BD-pTau217, NfL) for targeted biomarker quantification, the NULISA Dried Blood Spot Extraction Kit for remote sampling, and NULISAqpcr Custom Assay Development for bespoke biomarker panels. Software solutions (ARGO Command Center, NULISA Analysis Software, NULISAseqR R package) support data analysis. Services include the Technology Access Program for proof-of-concept studies and a network of Certified Service Providers for outsourced proteomics.
Differentiator
Problem solved
Functional benefit
Brands
- NULISA: Ultra-high sensitivity proteomics platform technology enabling attomolar-level protein detection with high multiplexing capabilities
- ARGO HT
- NULISAseq
- NULISAqpcr
- TAP (Technology Access Program)
Products and services
- ARGO HT System Fully automated, high-throughput precision proteomics instrument performing ultra-high sensitivity and multiplexed protein analysis. Integrates sample preparation, qPCR/NGS readout, and data analysis in one compact system, processing up to 288 samples per run batch with under 30 minutes hands-on time. Designed for pharma/biotech and academic research institutions.
- NULISAseq Neuro 220 Panel Multiplexed proteomics panel measuring 220 biomarkers from a single 10 µL sample, covering Alzheimer's, Parkinson's, TBI, ALS, MS, and Gliomas. Includes 12 highly specific assays for Tau protein isoforms (pTau217, pTau181, pTau205, pTau212, pTau231) and 25 Parkinson's disease biomarkers developed with the Michael J. Fox Foundation. Targets neuroscience researchers and drug developers.
- NULISAseq CNS Disease Panel 120 Multiplexed panel enabling ultra-sensitive quantification of 120+ neuro-specific and inflammatory proteins from 10 µL plasma or CSF. Includes brain-derived Tau isoforms (pTau217, pTau181, pTau231, tTau) for comprehensive tau pathology assessment from blood. Targets CNS disease researchers and translational scientists.
- NULISAseq Inflammation Panel 250 Comprehensive inflammatory response panel measuring 250+ proteins from 10 µL sample with attomolar sensitivity. Detects baseline levels of low-abundance cytokines for early detection of disease signatures across autoimmune, neuroinflammatory, and immune-oncology research. For immunology and inflammation researchers.
- NULISAseq Inflammation Panel AQ Quantifies 250+ biomarkers with absolute quantitation for 150+ targets. Ultra-high fg/mL sensitivity detects biomarker levels in normal, baseline, and disease samples. Designed for longitudinal tracking and clinical cohort studies in immunology research.
- NULISAseq Mouse Panel 120 Multiplexed panel of 120+ proteins designed specifically for murine experiments. Broadest coverage of immunology and only panel to include neurology content. Attomolar sensitivity detects low-abundant targets such as p-tau217 for pre-clinical studies. For pre-clinical and translational animal model researchers.
- NULISAqpcr AD 5-plex Assay Research-use-only multiplexed assay measuring five Alzheimer's blood-based biomarkers (BD-pTau217, NfL, Aβ42, GFAP, APOE4) from a single plasma sample. Consolidates multiple single-plex tests with enhanced sensitivity and streamlined workflow for Alzheimer's research.
- NULISAqpcr BD-pTau217 Assay Single-plex assay for precise detection of brain-derived pTau217 in blood or CSF using 10 µL sample. Uniquely specific to low molecular weight pTau217 isoform from CNS. fg/mL sensitivity with 7-point standard curve for absolute quantitation. For Alzheimer's researchers.
- NULISAqpcr NfL Assay Single-plex assay for precise detection of neurofilament light protein in serum or plasma. Attomolar sensitivity enables early neuroaxonal injury detection and monitoring across ALS, Alzheimer's, Parkinson's, MS, TBI, and stroke. For neurology researchers.
- NULISA Dried Blood Spot Extraction Kit Standardized workflow for recovering protein analytes from dried blood and plasma spots. Validated across Capitainer, Telimmune, Mitra, Tasso, and Whatman devices with 85-95% target detectability using 96-well filter-plate format for high-throughput processing. Enables decentralized, longitudinal, and population-scale research studies.
- NULISAqpcr Custom Assay Development Custom biomarker assay development service using NULISAqpcr technology. Researchers provide their own antibodies to create tailored assays with attomolar sensitivity. Requires 100 µg antibody input per target, generating enough material for 3,500+ samples. For researchers with specialized biomarker needs.
- Alamar Analysis Solutions Integrated data analysis software suite including ARGO Command Center (cloud-based run setup and QC), NULISA Analysis Software (QC, normalization, statistical analysis), and NULISAseqR R package for advanced bioinformatics. Supports proteomics data interpretation for ARGO HT users.
- Technology Access Program (TAP) Fee-for-service program providing researchers access to ultra-high sensitivity NULISA multiplex and single-plex assays for proof-of-concept data before purchasing the ARGO HT System. Includes Pro Services (full sample analysis with consultation and bioinformatics support up to 40 hours) and Custom Assay Development.
Quantifiable outcome
- 10,000x sensitivity improvement over traditional PLA and ELISA technologies
- +5 more outcomes
Companies that use Alamar Biosciences
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
Alamar Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability2 records
Feature6 records
Alamar Biosciences partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- SanoficoreSanofi joined Global Alzheimer's Platform Foundation's Bio-Hermes-002 observational study as newest partner. Alamar's NULISA technology is part of this study platform for biomarker analysis.
- BEVIMIminorBEVIMI will conduct a randomized, placebo-controlled clinical study utilizing Alamar's next-generation inflammatory biomarker panel to assess Uno Protect brain health formulation safety and biomarker responses.
- The Michael J. Fox Foundation for Parkinson's ResearchcoreCollaboration supporting development of the NULISAseq Neuro 220 Panel, which includes 15 new Parkinson's disease biomarkers and 12 Tau protein isoform assays developed in collaboration with MJFF.
- IQVIA LaboratoriescoreCertified Service Provider offering development, validation and implementation of multiplexed assays using NULISA platform for biopharma customers.
- BiognosyscoreCertified Service Provider offering specialty proteomics services combining mass spectrometry with NULISA multiplex assays.
- Frontage LabscoreCertified Service Provider offering biomarker assay development, validation, and sample analysis services.
- GeneWorkscoreExclusive distributor for Australia and New Zealand, providing local sales and support for NULISA and ARGO HT products.
- GenomaxcoreExclusive distributor for Singapore, providing local sales and support for Alamar products.
- Scrum, Inc.coreExclusive distributor for Japan, providing local sales and support for NULISA and ARGO HT products.
- SpincocoreExclusive distributor for India, providing local sales and support for Alamar products.
- PhileKoreacoreExclusive distributor for South Korea, providing local sales and support.
- GeneTiCA GroupcoreExclusive distributor for Czech Republic, Slovakia, Poland, and Hungary.
- PensabiocoreExclusive distributor for Sao Paulo, Brazil, covering South America.
- Global Alzheimer's Platform FoundationcoreStrategic collaboration to join Bio-Hermes studies (Bio-Hermes-001 and Bio-Hermes-002) comparing blood-based and digital biomarkers across diverse populations. Alamar gains access to biospecimens and data from over 1,000 participants, contributing its NULISA proteomics technology to the research platform.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Alamar Biosciences competitors and assessment
Company assessmentDirect peers
- Olink Holding (Thermo Fisher Scientific): Olink's proximity extension assay (PEA) platform is Alamar's most direct competitor in high-multiplex protein biomarker detection. Acquired by Thermo Fisher Scientific in 2024 for ~$3.1B, the combination creates a peer with massive scale, established pharma relationships, and bundled instrument pricing that competes head-to-head with NULISA in neurodegenerative and inflammation research.
- SomaLogic (Standard BioTools): SomaLogic's SomaScan aptamer-based platform measures 7,000+ proteins from a single sample and is the broadest-multiplex direct competitor to NULISAseq. Alamar's CSO Steve Williams was previously CMO at SomaLogic, and the two platforms compete for pharma biomarker discovery budgets.
- Quanterix: Quanterix's Simoa single-molecule array technology provides ultra-sensitive single-plex and multiplex protein detection, particularly strong in neurology (NfL, pTau) research. Direct competitor in the ultra-high-sensitivity biomarker segment where NULISAqpcr assays overlap, especially for Alzheimer's blood-based biomarkers.
Emerging players
- Seer: Seer's Proteograph platform uses engineered nanoparticle-based enrichment with mass spectrometry for unbiased proteomics, targeting biomarker discovery at depth. Less directly overlapping than Olink or SomaLogic, but competes for the same pharma translational proteomics budget.
- Nautilus Biotechnology: Nautilus is developing a single-molecule proteomics platform aiming to measure the full proteome. While still pre-commercial, it represents a long-term competitive threat to NULISA's high-multiplex, ultra-sensitive positioning if it achieves commercial scale.
Broad incumbents
- 10x Genomics: 10x Genomics sells Chromium and Xenium platforms for single-cell genomics and spatial biology, increasingly expanding into multi-omics including protein readout. Highly relevant as Alamar's CFO Justin McAnear was previously CFO at 10x and led its 2019 IPO, and both target overlapping translational research customers.
- Bio-Techne: Bio-Techne is a diversified life sciences tools company offering Proteome Profiler arrays, ELISA kits, and Luminex-based multiplex assays. It serves overlapping pharma/biotech and academic customers with broader proteomics reagent menus but at lower sensitivity than NULISA's attomolar platform.
- Bruker: Bruker's timsTOF and other mass spectrometry platforms power proteomics workflows including those run by Biognosys (an Alamar CSP partner). Competes for translational proteomics research dollars, especially where unbiased discovery rather than targeted multiplex panels is required.
Others
- Illumina: Illumina is both a sequencing platform provider that NULISAseq multiplex workflows depend on (NextSeq, NovaSeq validated configurations) and an investor via Illumina Ventures. Critical infrastructure partner whose sequencing reagent pricing and roadmap directly impact Alamar's multiplex panel economics.
- Element Biosciences: Element's AVITI sequencing platform is validated for NULISAseq readout, providing Alamar with a non-Illumina sequencing option. Relevant as an alternative-NGS partner that diversifies Alamar's ecosystem dependency and reflects the broader sequencing landscape the platform navigates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights8 records
Customer concentration
Alamar Biosciences social profiles
Digital presenceAlamar Biosciences compliance and trust
Trust signalCompliance2 records
Alamar Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alamar Biosciences leadership team
Management profileNumber of profiles
Profiles12 records
Alamar Biosciences funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alamar Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alamar Biosciences
What does Alamar Biosciences do?
Alamar Biosciences develops and commercializes the proprietary NULISA (NUcleic acid Linked Immuno-Sandwich Assay) proteomics platform alongside the ARGO HT automated instrument system. The company sells multiplexed assay panels (NULISAseq) and single-plex qPCR assays (NULISAqpcr) for ultra-high sensitivity detection of protein biomarkers in research applications targeting neurology, immunology, and oncology. Products are sold to pharmaceutical companies, biotech firms, academic medical centers, and contract research organizations across more than 25 countries.
Is Alamar Biosciences a public or private company?
Alamar Biosciences is a public company. It is classified as public and is currently ipo.
When was Alamar Biosciences founded?
Alamar Biosciences was founded in 2018. It employs 101 to 250 people.
Where is Alamar Biosciences based?
Alamar Biosciences is headquartered in Fremont, United States, in the North America region.
How does Alamar Biosciences make money?
Four revenue lines are on record. ARGO HT Instrument Sales are the primary driver. The others are NULISAseq Panel Consumables, NULISAqpcr Assay Consumables and technology Access Program (TAP).
Who are Alamar Biosciences's main competitors?
Direct peers on record are Olink Holding (Thermo Fisher Scientific), SomaLogic (Standard BioTools) and Quanterix. Emerging players are Seer and Nautilus Biotechnology. Broad incumbents are 10x Genomics, Bio-Techne and Bruker. Others are Illumina and Element Biosciences.
Does Alamar Biosciences have an API?
No public API is recorded for Alamar Biosciences.
What industry is Alamar Biosciences in?
Alamar Biosciences's product category is Precision Proteomics Instrumentation. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 334516 and its SIC code is 3826.